Skip to main content
Erschienen in: Reactions Weekly 1/2014

01.12.2014 | Case report

Anastrozole

Urticarial vasculitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Bock VL, et al. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australasian Journal of Dermatology 55: 282-285, No. 4, Nov 2014. Available from: URL: http://doi.org/10.1111/ajd.12110 - AustraliaPubMedCrossRef Bock VL, et al. Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australasian Journal of Dermatology 55: 282-285, No. 4, Nov 2014. Available from: URL: http://​doi.​org/​10.​1111/​ajd.​12110 - AustraliaPubMedCrossRef
Metadaten
Titel
Anastrozole
Urticarial vasculitis: case report
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2014
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-014-5841-z

Weitere Artikel der Ausgabe 1/2014

Reactions Weekly 1/2014 Zur Ausgabe

Case report

Sunitinib

Case report

Ciclosporin